Abivax S.A. (0RA9.L)
0RA9.L Stock Price Chart
Explore Abivax S.A. interactive price chart. Choose custom timeframes to analyze 0RA9.L price movements and trends.
0RA9.L Company Profile
Discover essential business fundamentals and corporate details for Abivax S.A. (0RA9.L) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
IPO Date
30 Sept 2016
Employees
69.00
Website
https://www.abivax.comCEO
Marc M. P. de Garidel
Description
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.
0RA9.L Financial Timeline
Browse a chronological timeline of Abivax S.A. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 23 Mar 2026
Upcoming earnings on 11 Aug 2025
Revenue estimate is €1.19M.
Earnings released on 2 Jun 2025
EPS came in at -€1.50 falling short of the estimated -€1.46 by -2.77%, while revenue for the quarter reached €5.69M, beating expectations by +82.71%.
Earnings released on 15 Nov 2024
EPS came in at -€1.30 surpassing the estimated -€1.37 by +5.52%, while revenue for the quarter reached €6.79M, beating expectations by +99.12%.
Earnings released on 2 Apr 2024
EPS came in at -€1.91 falling short of the estimated -€0.85 by -124.36%, while revenue for the quarter reached €2.25M, missing expectations by -2.39%.
Earnings released on 30 Jun 2023
EPS came in at -€1.45, while revenue for the quarter reached €2.25M.
Earnings released on 31 Dec 2022
EPS came in at -€1.81 falling short of the estimated -€1.76 by -2.66%, while revenue for the quarter reached €2.25M.
Earnings released on 30 Jun 2022
EPS came in at -€1.76, while revenue for the quarter reached €2.23M.
Earnings released on 31 Dec 2021
EPS came in at -€1.48.
Earnings released on 30 Jun 2021
EPS came in at -€1.13.
Earnings released on 31 Dec 2020
EPS came in at -€1.55, while revenue for the quarter reached €14.00K.
0RA9.L Stock Performance
Access detailed 0RA9.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.